Actuate Partners

Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers. The company's primary focus is the inhibition of glycogen synthase kinase-3 beta (GSK-3β), a master regulator of pathways involved in tumor survival and resistance. Its lead drug candidate, elraglusib (formerly 9-ING-41), is a small molecule inhibitor currently in Phase 2 clinical trials for metastatic pancreatic cancer and Phase 1/2 trials for pediatric and adult solid tumors. Actuate is also advancing an oral formulation of elraglusib to enhance patient compliance and expand its therapeutic reach. The company listed on the Nasdaq in 2024 to fund the continued development of its oncology pipeline.